Wellness program to improve quality of life in NMOSD patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project investigates the effectiveness of a structured wellness program designed to enhance the quality of life for individuals with Neuromyelitis Optica Spectrum Disorder (NMOSD). The pilot study will involve 20 participants who will be randomly assigned to either an immediate intervention group or a control group that starts the program after six months. The wellness intervention includes services from physical therapists, dietitians, social workers, and cognitive therapists, with assessments conducted at baseline, 12 weeks, and 6 months to evaluate outcomes. The primary focus is on measuring quality of life using the MS-Quality of Life -54 scale.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Adults (age ≥18) with NMOSD diagnosed with 2015 NMOSD clinical criteria.
* All EDSS scores will be considered in order to make the intervention accessible to all patients regardless of disability.
* All patients regardless of treatment type will be considered.

Exclusion criteria:

* Age\<18
* Inability to voluntarily provide consent for study participation
* Inability to participate in study evaluation and/or endpoint measures, or participation in another concurrent randomized controlled trial or wellness based intervention.
* Any patients with a relapse within 30 days of randomization or any patients with medical restrictions on physical activity will be excluded.
* Any patients who begin stimulants and/or dalfampridine between enrollment and randomization will be excluded.

Where it's running

• Corinne Goldsmith Dickinson Center for MS at Mount Sinai
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Sammita Satyanarayan, MD — Icahn School of Medicine at Mount Sinai
• Study coordinator: Susan Filomena
• Email: susan.filomena@mssm.edu
• Phone: 212-241-3841

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• QH103 (universal CD19 CAR-γδT) cell injections for relapsed or treatment‑resistant antibody-driven neurological autoimmune diseases

  This Phase 1 test will see if QH103 (universal CD19 CAR-γδT) cell injections are safe and tolerated in adults with relapsed or treatment‑resistant antibody-mediated neurological diseases such as MS, NMOSD, AE, CIDP, or MG.

  Recruiting Phase 1 Tongji Hospital · Wuhan, Hubei · NCT07526493

• HBI0101 CAR-T for refractory B‑cell autoimmune rheumatic diseases

  This will test a single infusion of HBI0101 CAR‑T cells in adults with severe, treatment‑resistant B‑cell autoimmune diseases such as SLE, systemic sclerosis, idiopathic inflammatory myopathy, rheumatoid arthritis, or primary progressive MS.

  Recruiting Phase 1 Hadassah Medical Organization · Jerusalem · NCT07085676

• Safety of Ultomiris during pregnancy

  This study looks at how safe Ultomiris is for pregnant women and their babies to see if it causes any problems during pregnancy and breastfeeding.

  Recruiting at 4 sites Alexion Pharmaceuticals, Inc. · Boston, Massachusetts and 6 other locations · NCT06312644

• Satralizumab in the early treatment of NMOSD attacks: a multicenter real-world study

  This study tests whether starting Satralizumab during an NMOSD attack is safe and helpful for adults with AQP4-IgG–positive NMOSD.

  Recruiting Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT07762872

• Pregnant Women with Neuroimmune Diseases: A long-term follow-up study

  This study follows women with neuroimmune diseases and healthy controls through pregnancy and up to ten years to see how pregnancy affects disease activity and outcomes for both mother and baby.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT07653984

• Modified Zipper Therapy for AQP4‑antibody–positive NMOSD acute attacks

  This trial will test whether adding immediate eculizumab to high‑dose steroids and plasma exchange helps adults with AQP4‑antibody–positive NMOSD recover better from acute attacks.

  Recruiting Phase 3 Tianjin Medical University General Hospital · Tianjin · NCT07420296

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.